Recently, ThalysBio has been successfully recognized as a provincial specialized, special and new “small giant” enterprise. To be recognized as a specialized, precise, characteristic and innovative “Little Giant” enterprise, one needs to meet six indicators: specialization (focus / deep cultivation), precision (specification / system), characterization (unique / competitive), innovation (innovation / independence), chain (industrial chain...
ThalysBio hemostasis reagents have a wide range of customer applications with market-proven quality and excellent performance. Recently, our products including APTT, PT, TT, FIB and AT-III coagulation reagents have been evaluated by an internationally renowned third-party quality control vendor, Landau, UK, and provide three levels of quality control and assignment of level 1, level 2,...
★The significance of timely diagnosis and prognostic monitoring of heart failure CCTV recently reported that the number of current cardiovascular disease patients in China is as high as 330 million, with its incidence and mortality rates still topping the list of common diseases, with two out of every five deaths die of cardiovascular disease, according...
© 2022 Thalysbio. All rights reserved 鄂ICP备2023001689号-1